A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Internal tandem duplications in fms-like tyrosine kinase 3 (FLT3-ITDs) are common in acute myeloid leukemia (AML) and confer a poor prognosis. A sensitive and specific assay for the detection of minimal residual disease (MRD) in FLT3-ITD mutated AML could guide therapy decisions. Existing assays for...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Blood Adv
Huvudupphovsmän: Levis, Mark J., Perl, Alexander E., Altman, Jessica K., Gocke, Christopher D., Bahceci, Erkut, Hill, Jason, Liu, Chaofeng, Xie, Zhiyi, Carson, Andrew R., McClain, Valerie, Stenzel, Timothy T., Miller, Jeffrey E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2018
Ämnen:
Myeloid Neoplasia
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916006/
https://ncbi.nlm.nih.gov/pubmed/29643105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018015925
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk